A Wettability Gradient Synergistic Bionic Wedge-Shaped Track for Ultrafast and Long-Distance Spontaneous Transport of Droplets by Xinghai Zhong (21450285)

“…To address the aforementioned challenges, we developed a bionic wedge-shaped track on the copper (Cu) substrate inspired by the cone-shaped thorn of cactus for liquid spontaneous transport. …”

A Wettability Gradient Synergistic Bionic Wedge-Shaped Track for Ultrafast and Long-Distance Spontaneous Transport of Droplets by Xinghai Zhong (21450285)

“…To address the aforementioned challenges, we developed a bionic wedge-shaped track on the copper (Cu) substrate inspired by the cone-shaped thorn of cactus for liquid spontaneous transport. …”

Schematic diagram of numerical simulation model. by Mengyun Li (7490870)

“…Finally, using the established prediction method, we calculated the limiting conditions for the existence of weak water-flushed zones in the X oil field test area. …”

The result of molecular dynamics simulation. by Ashraf Attia Mahmoud (21262201)

“…The docking research indicated that these mutations decreased the binding affinity for DNA, with R273C, R280G, G266E, and G105C displaying the most significant differences. …”

Result of the phenotypic analysis. by Ashraf Attia Mahmoud (21262201)

“…The docking research indicated that these mutations decreased the binding affinity for DNA, with R273C, R280G, G266E, and G105C displaying the most significant differences. …”

Type of Mutations. by Ashraf Attia Mahmoud (21262201)

“…The docking research indicated that these mutations decreased the binding affinity for DNA, with R273C, R280G, G266E, and G105C displaying the most significant differences. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

SEM images of cobalt-based catalysts supported on Al₂O₃ at different magnifications. by Ning Zuo (17295415)

Baseline analysis, nominal factors. by Hiroaki Yoshikawa (4615801)

“…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”

Minimal dataset for the study. by Hiroaki Yoshikawa (4615801)

“…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”

Baseline analysis, continuous factors. by Hiroaki Yoshikawa (4615801)

“…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”

Multivariable analysis between 2006 and 2018. by Hiroaki Yoshikawa (4615801)

“…Conversely, the occurrence of myasthenic crisis and current MG-ADL scores were lower in 2018. Regarding treatment, the utilization of tacrolimus, plasma exchange (PE), and intravenous immunoglobulin (IVIg) significantly increased between 2006 and 2018. …”

<b> </b> Energy efficiency and gas volume comparison. by Ning Zuo (17295415)

“…CO₂ yield was higher in the control group at lower temperatures, while the integrated system consistently produced more biochar and biogas. …”

Model validation of kinetic parameters. by Ning Zuo (17295415)

“…CO₂ yield was higher in the control group at lower temperatures, while the integrated system consistently produced more biochar and biogas. …”

SPIRIT Schedule of Enrollment. by Asma Salari (21432948)

Measuring muscle strength [49]. by Asma Salari (21432948)